Included in this total were $4 million of donor acquisition deal costs, which we have included as a pro forma item in our adjusted operating income adjusted EBITDA, and adjusted EPS calculations. Excluding these costs, RSG&A costs were actually 3.5 million lower than the previous year, despite 2.3 million of higher annual incentive costs and stock comp costs compared with the fourth quarter a year ago. This improved level of RSG&A was due to several factors. We had lower selling costs of 1.4 million, resulting from cost-saving measures, including lower headcount and limited travel.

May 26, 2021 / CFO / receipt, needs a key / Greg Rustwitz, CFO | earnings call 2021-05-26 | transcript fd237d86-1d43-4b08-a2b0-0846042c0c85 | chars 9204-9792 | segment 9